drugset / Trial / NCT06642909
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is a multicenter, randomized, open label, cyclosporine controlled Phase II trial aimed at evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of Zuberitamab in patients with primary membranous nephropathy, and exploring the Phase III dosing regimen, sample size, and endpoint evaluation time
Timeline
- Start
- 2024-11-13
- Primary completion
- 2027-03-31
- Completion
- 2027-05-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclosporine | Peptide | 3.5 mg/kg | Oral |
| Subject | Zuberitamab | Monoclonal antibody | 600 mg | — |
| Subject | Zuberitamab | Monoclonal antibody | 1000 mg | — |